Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Anaptys Named a BioSpace 2024 Best Places to Work Winner

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors